BioSyent, based in Mississauga, Ontario, announced on February 9 that it entered into an agreement to acquire Oral Science Inc.
The purchase price is $25.5 million CAD cash (nearly $18.8 million USD), as well as 234,192 BioSyent common shares at a price of $12.81 CAD per share ($9.44 USD), representing $3 million CAD, or more than $2.2 million USD, in aggregate.
Oral Science is a privately owned Canadian distributor of specialized healthcare products for dental hygiene and oral health, based in Brossard, Quebec. According to the original deal press release for the trailing twelve months ended September 30, 2025, Oral Science generated gross revenues in excess of $30 million CAD (more than $22.1 million USD), and EBITDA in excess of $4 million (more than $2.9 million USD).
BioSyent is a growth-oriented specialty pharmaceutical company which acquires pharmaceutical products. In its third quarter 2025 financial report, the company announced 12-month trailing revenue of nearly $42.2 million CAD (more than $310.9 million USD).
This acquisition is expected to be accretive, with incremental profit and cash flows in 2026. Wildeboer Dellelce LLP is acting as legal counsel and KPMG LLP is acting as financial advisor to BioSyent.
According to data captured in the LevinPro HC database, this transaction marks the seventh healthcare product distributor deal of the year. Throughout 2025, there were 38 healthcare product distributor transactions reported. The most active buyer in the specialty is Asker Healthcare Group, which has announced 11 acquisitions in the last 13 months.
